Elevance Health insider trading
Every open-market purchase and sale by Elevance Health's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Elevance Health’s insiders pay?
From February 8, 2010 to October 23, 2026, 41 insiders reported 9 open-market purchases and 134 sales not made under a pre-set plan in Elevance Health. Twelve months after each purchase was reported, the shares were +11.9% against the S&P 500 on average (median +16.1%), over 6 purchases with a full year of prices; 67% beat the index. After sales, the shares moved +4.3% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 3, 2020 into $31,946 by November 2, 2026, +18.8% a year. It held shares 56% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $17,722 (+8.9% a year), and held throughout $25,669 (+15.0%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Penczek Ronald W | CAO & Controller | 0 | — | — | 23 | +5.2% (21) | June 15, 2026 |
| Hill Julie A | Director | 0 | — | — | 10 | +5.2% (10) | May 24, 2021 |
| Zielinski Thomas C | EVP & General Counsel | 0 | — | — | 10 | +8.1% (10) | November 4, 2020 |
| Dixon Robert L Jr | Director | 0 | — | — | 8 | −7.1% (7) | June 12, 2026 |
| Cannon John | EVP, GC & Chief PAO | 0 | — | — | 7 | +10.3% (7) | December 16, 2013 |
| Nussbaum Samuel R Md | EVP & Chief Medical Officer | 0 | — | — | 7 | +12.4% (7) | September 15, 2014 |
| Kendrick Charles Morgan Jr | EVP & President, Commercial | 0 | — | — | 6 | −29.8% (5) | March 9, 2026 |
| Goulet Kenneth R | EVP, Commercial & Specialty | 0 | — | — | 5 | +1.8% (5) | February 20, 2015 |
| Ryan William J | Director | 0 | — | — | 5 | +16.8% (5) | July 29, 2016 |
| Brown Randal L | EVP & Chief HR Officer | 0 | — | — | 4 | +14.2% (4) | September 6, 2013 |
| Deveydt Wayne S | EVP & Chief Financial Officer | 0 | — | — | 4 | +8.9% (4) | August 7, 2014 |
| Jobe Warren Y | Director | 0 | — | — | 4 | +17.1% (4) | August 28, 2013 |
| Mccarthy Gloria M | EVP & Chief Administrative Off | 0 | — | — | 4 | +19.6% (4) | March 14, 2016 |
| Schaefer George A Jr | Director | 0 | — | — | 4 | +28.2% (4) | February 3, 2014 |
| Boudreaux Gail | President and CEO | 3 | +8.7% (2) | 50% | 0 | — | July 17, 2026 |
| Burke Sheila P | Director | 0 | — | — | 3 | −17.7% (3) | November 7, 2011 |
| Sassi Brian A | President & CEO Cons, EVP | 1 | −26.3% (1) | 0% | 2 | −21.9% (2) | August 12, 2011 |
| Baker Lenox D Jr Md | Director | 0 | — | — | 2 | −1.3% (2) | March 11, 2013 |
| Bayh Susan B | Director | 0 | — | — | 2 | −13.3% (2) | May 23, 2012 |
| Beer Lori A | EVP, Specialty Businesses & IT | 0 | — | — | 2 | +22.6% (2) | June 3, 2013 |
| Bush William H T | Director | 0 | — | — | 2 | −17.6% (2) | May 9, 2011 |
| Gallina John E | SVP & Chief Accounting Officer | 0 | — | — | 2 | +27.0% (2) | June 4, 2014 |
| Kaye Mark | EVP & CFO | 0 | — | — | 2 | −37.7% (1) | October 23, 2026 |
| Riegle Donald W Jr | Director | 0 | — | — | 2 | −2.5% (2) | September 15, 2010 |
| Schneider Ryan M. | Director | 2 | +35.9% (2) | 100% | 0 | — | July 26, 2021 |
| Ward Jackie M | Director | 0 | — | — | 2 | −11.4% (2) | February 21, 2012 |
| Collis Steven H | Director | 1 | — | — | 0 | — | March 6, 2026 |
| Devore Susan D. | Director | 1 | +8.7% (1) | 100% | 0 | — | August 21, 2025 |
| Fluegel Bradley M | EVP, Chief Strategy Officer | 0 | — | — | 1 | +12.1% (1) | November 9, 2010 |
| Griffin Brian T | EVP & CEO, IngenioRx | 0 | — | — | 1 | +10.6% (1) | May 7, 2018 |
| Haytaian Peter D | EVP & President, Commercial | 0 | — | — | 1 | −7.0% (1) | October 30, 2019 |
| Levine Harlan A | EVP, CHS | 0 | — | — | 1 | +30.0% (1) | September 5, 2012 |
| Lewis Dijuana K | Pres & CEO CHS and EVP | 0 | — | — | 1 | +28.7% (1) | May 24, 2010 |
| Liss Victor S | Director | 0 | — | — | 1 | −5.6% (1) | March 12, 2010 |
| Mays William G | Director | 0 | — | — | 1 | −15.6% (1) | February 11, 2010 |
| Miller Martin L | SVP & Chief Accounting Officer | 0 | — | — | 1 | +18.0% (1) | December 16, 2010 |
| Norwood Felicia F | EVP & President,Gov Health Ben | 0 | — | — | 1 | −31.1% (1) | April 25, 2024 |
| Peru Ramiro G | Director | 1 | — | — | 0 | — | July 17, 2026 |
| Samitt Craig E | EVP & President, DBG | 0 | — | — | 1 | +9.7% (1) | July 27, 2018 |
| Todt Blair Williams | EVP, CLO & CAO | 0 | — | — | 1 | −46.3% (1) | December 15, 2023 |
When several insiders traded Elevance Health
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Elevance Health in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −16.0% against the index. After 18 selling crowds, +1.3%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| September 30, 2026 | 2 buying | not yet | not yet | not yet |
| August 29, 2025 | 2 buying | +0.5% | −16.0% | +9.7% |
| April 30, 2025 | 3 selling | −46.7% | −43.9% | −40.9% |
| April 30, 2024 | 3 selling | −9.1% | −38.5% | −35.7% |
| May 28, 2021 | 3 selling | −13.7% | −5.0% | +32.1% |
| June 30, 2020 | 4 selling | −9.1% | −1.2% | +6.2% |
| December 31, 2019 | 3 selling | −5.7% | −7.9% | −12.4% |
| July 31, 2019 | 4 selling | −9.6% | −20.4% | −15.8% |
| November 30, 2018 | 3 selling | +0.6% | −7.7% | −14.8% |
| September 28, 2018 | 3 selling | +9.6% | +6.3% | −14.9% |
| May 31, 2018 | 5 selling | +13.0% | +30.1% | +23.0% |
| August 31, 2017 | 3 selling | +12.7% | +8.1% | +17.3% |